Clarification of drug sensitivity in leukemia cells by comprehensive analysis by microarray technology

Research Project

Project/Area Number	15K19609
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Pediatrics
Research Institution	Hamamatsu University School of Medicine
Principal Investigator	Sakaguchi Kimiyoshi 浜松医科大学, 医学部附属病院, 講師 (00402280)
Project Period (FY)	2015-04-01 – 2018-03-31
Project Status	Completed (Fiscal Year 2017)
Budget Amount *help	¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000) Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000) Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000) Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords	薬剤反応性 / がん / 遺伝子 / マイクロアレイ
Outline of Final Research Achievements	Decitabine, a DNA demethylating agent, showed improved drug sensitivity in acute lymphocytic leukemia cell lines, CCRF-CEM, Jurkat, BALL-1, and NALM-6. Three genes, MEST, NDRG4, and ZNF750, are known as tumor suppressor genes, and observed DNA demethylation and increase in mRNA expression level by the addition of decitabine. Therefore, we considered these genes are the candidate genes concerning drug sensitivity in leukemia cells. However, further study was required to whether these genes are truly concerning drug sensitivity.

Report

(4 results)